Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A National Multi-center, Double Blinded, Randomized, Placebo Controlled Study
Phase of Trial: Phase IV
Latest Information Update: 29 Jan 2018
Price : $35 *
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms STOP IT
- 31 Aug 2018 Biomarkers information updated
- 17 Oct 2015 Planned number of patients changed from 139 to 136, as reported by European Clinical Trials Database.
- 30 Oct 2014 Planned End Date changed from 1 Jul 2015 to 1 Nov 2016.